STUDY QUESTION: Is the total dose of exogenous gonadotropins associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women?
Introduction
Gonadotropins are the primary regulators of follicular development and cytodifferentiation in the ovary (Gougeon, 1996) . In ART cycles, the most commonly used gonadotrophins are urinary human menopausal gonadotropin and recombinant FSH (Fatemi et al., 2012) . The goal of ovarian stimulation with exogenous gonadotropins is to induce the ongoing development of multiple dominant follicles and to increase the number of oocytes available for fertilization (Dodson and Haney, 1991; de Ziegler et al., 1998) .
Recent studies have asserted that the success of implantation seems to be mainly determined by the chromosomal status of embryos (Capalbo et al., 2014) . Given the clinical significance of embryonic euploidy, PGS treatment is adopted to identify aneuploid embryos (Baart et al., 2006; Dahdouh et al., 2015) . Many researchers have been exploring the influencing factors of embryonic aneuploidy (Braga et al., 2012; Goldman et al., 2015; Demko et al., 2016; Gat et al., 2017) , but the mechanisms underlying aneuploidy are complex and poorly understood. Most chromosome abnormalities, as well as most first trimester embryonic aneuploidy, were thought to originate from female-specific error in the first meiotic division (Hunt et al., 1995; Pacchierotti et al., 2007) . Some researchers speculated that when exogenous gonadotropins were administered to stimulate multiple follicular development, the discrimination of regulating the suitable alignment for the meiotic spindles may be exacerbated Patrizio and Sakkas, 2009) .
Recently, mild stimulation protocols, which typically use a low dose of exogenous gonadotropins, have risen in popularity (Verberg et al., 2009b) . A mild IVF cycle was defined as the method 'when FSH or HMG is administered at lower doses and/or for a shorter duration in a GnRH antagonist co-treated cycle or when oral compounds (antiestrogens or aromatase inhibitors) are used, either alone or in combination with gonadotrophins. HCG injection and luteal support are also administered' (Nargund et al., 2007) . The debate on the benefits and challenges of mild stimulation protocols and conventional protocols has been intense (Alper and Fauser, 2017) . Previous investigators reported that the odds of embryonic aneuploidy were reduced after mild stimulation protocols (Baart et al., 2007) . However, Verpoest et al. (2008) illustrated that embryonic aneuploidy was present even in the absence of ovarian stimulation.
It has been theorized that ovarian stimulation interferes in the natural selection of dominant follicles, increasing the errors in the division of oocytes and genomic imprinting (Sato et al., 2007) . However, Labarta et al. (2012) demonstrated that moderate ovarian stimulation may not be associated with the rate of embryonic aneuploidy. Recent studies reported that the total dose of exogenous gonadotropins did not significantly affect the rate of aneuploidy (Barash et al., 2017; Sekhon et al., 2017) . It is important to note that the mean dose of exogenous gonadotropins administrated in these two studies was far more than that used in the Han Chinese population.
Considering the different doses of the exogenous gonadotropins administrated for ovarian stimulation in different regions and races, we determined whether an association exists between the total dose of exogenous gonadotropins and blastocyst aneuploidy in the Han Chinese population. Additionally, the second goal was to determine whether the number of oocytes retrieved was associated with the blastocyst aneuploidy rate. Given the important clinical significance of pregnancy rates, the relation between gonadotropins dose, number of oocytes retrieved and pregnancy and live-birth rates was also explored.
Materials and Methods

Study population
A retrospective comparative study was conducted. Anonymous data were obtained from the Centre for Reproductive Medicine, Provincial Hospital affiliated to Shandong University. Between January 2013 and June 2017, the Laboratory of Reproductive Medicine performed 3219 embryo biopsies from 1088 PGS cycles for 24-chromosome PGS. The indications for performing PGS were advanced maternal age (≥38 y.o.), repeated implantation failure in IVF cycles, recurrent foetal aneuploidy and recurrent miscarriage. We omitted patients who had natural cycles, those using embryos that were transferred on Day 3 and those who had chromosomal abnormalities or single gene disorders. In our study, the patient characteristics were evaluated, including age, chromosomal status and physical examination. Other parameters, including basal FSH and number of oocytes retrieved, were also recorded.
Ethics approval
This study was approved by the ethics committees of Reproductive Medicine Centre of Shandong University.
Study procedures
All women underwent appropriate ovarian stimulation protocols. There were four stimulation protocols: long GnRH agonist (538 PGS cycles), short GnRH agonist (379 PGS cycles), antagonist (118 PGS cycles) and mild stimulation protocols (53 PGS cycles). The doses of recombinant FSH (Gonal-f, Merck Serono, Germany; or Puregon, MSD, USA) and urinary human menopausal gonadotropin (Menopur, Ferring, Switzerland) were adjusted according to the ovarian response, as monitored by the measurement of serum sex steroids and ultrasonography. HCG at a dose of 4000-10 000 IU was used to trigger oocyte maturation when follicles measured 18 mm or more. Oocyte retrieval was performed 36 h after the trigger.
All oocytes were inseminated by intracytoplasmic sperm injection and the embryos were cryopreserved through vitrification. The embryo scoring was conducted by morphologic criteria (Gardner et al., 2000) . Briefly, blastocysts were graded on a 1-6 scale determined by the degree of expansion and hatching status. The inner cell mass (ICM) was scored according to the number of cells. Many ICM cells packed together tightly represented the best grade (A), whereas grade B showed several ICM cells loosely grouped. The worst grade (C) was when there were very few ICM cells. In parallel, trophectoderm (TE) was considered of good quality if many cells formed a cohesive epithelium. Many TE cells forming multiple epithelial layers represented the best grade (A). Grade B showed few TE cells consisting of a loose epithelium and very few large TE cells represented the worst grade (C). Three experienced embryologists scored the blastocysts using consistent lab conditions and scoring criteria. In addition, embryonic scoring was checked by the section director. Poor-quality blastocysts were not biopsied.
A total of 3219 blastocysts were genetically screened using arraycomparative genomic hybridization (array-CGH) and the diagnoses were confirmed by three experienced technicians. The biopsied cells from blastocyst trophectoderms were placed in PCR tubes containing 2.5 μl 1 × PBS. The samples and referenced male DNA were amplified according to the protocol using the SurePlex whole genome amplification kit (Illumina, San Diego, CA, USA). Next, the amplified DNA samples and reference male DNA (8 μl for each) were labelled by using the fluorescent labelling system (Illumina). The labelling time was~3 h with DNA resuspended in hybridization buffer and hybridized overnight under a 24sure microarray (Illumina). The hybridized 24sure slides were washed to remove the unhybridized DNA and subsequently laser-scanned at 10 μm (InnoScan 900, Innopsys, FR). The scanned images were analysed using BlueFuse Multi software (BlueGnome).
At the third (or later) menstrual cycle after the retrieval of oocytes, natural ovulation was monitored by ultrasonography. Luteal-phase support was initiated on the day of ovulation. If the natural ovulation cycle was cancelled due to anovulation or poor endometrial development, an artificial cycle was used for endometrial preparation. Luteal-phase support was initiated when the endometrial thickness reached at least 7 mm and continued daily until 3 months of gestation with 20 mg twice daily of oral dydrogesterone (Duphaston, Abbott, USA) and either 200 mg daily of vaginal progesterone capsules (Utrogestan, Besins Manufacturing Belgium) or 90 mg daily of vaginal progesterone gel (Crinone; Merck Serono).
A single euploid embryo was chosen for transfer. Biochemical pregnancy was defined as HCG > 10 mIU/ml, as measured 2 weeks after the embryo transfer. Clinical pregnancy was defined as an intrauterine gestational sac at 35 days after the embryo transfer, as detected on ultrasonography. Ongoing pregnancy was defined as a foetus present in uterus with heart motion at 11-12 weeks of gestation, and live birth was defined as delivery of a viable infant at 28 weeks or more of gestation after the embryo transfer.
Statistical analysis
Patients were categorized into three groups according to the total dose of gonadotropins (<1500, 1500-3000 and >3000 IU per PGS cycle), into two age groups (<35 and ≥35 y.o.) and into four groups by the number of oocytes retrieved (1-5, 6-10, 11-15 and >15 oocytes).
Chi-squared analysis was appropriate for the comparison of the embryonic aneuploid rate (number of aneuploid embryos/total number of embryos biopsied) and pregnancy rates (biochemical pregnancy, clinical pregnancy, ongoing pregnancy and live-birth rate) in different groups. For continuous variables, the Kruskal-Wallis H test was performed to assess the differences within groups. Multiple logistic regression was performed to evaluate the relationship between the confounding factors, the exogenous gonadotropins dose and the blastocyst aneuploidy rate. The confounding factors included female age, BMI, basal FSH, number of oocytes retrieved, HCG dosage, proportion of HMG, number of previous cycles and ovarian stimulation protocol. Odds ratios and 95% CI were calculated between the two categorical variables. A P-value of <0.05 was considered statistically significant. Analyses were performed using SPSS version 20.0 (Chicago, IL, USA) and Graphpad Prism 7 (Graphpad Software, San Diego, CA, USA).
Results
There were 1088 PGS cycles available for analysis. The total number of euploid embryos was 1690, of the 3219 embryos genetically screened using array-CGH. The embryonic euploidy rate was 52.5% (95% CI: 48.5-53.0%). The patient clinical characteristics and cycle parameters are presented in Table I .
Women with advanced maternal age (≥35 y.o.) had an increased exogenous gonadotropin dose used for PGS compared with younger women (<35 y.o.): 2084.2 ± 899.4 IU in the group of women with advanced maternal age and 1897.2 ± 824.2 IU in the group with younger women. Similarly, the embryonic aneuploidy rate increased with advanced maternal age: 59.3% (95% CI: 57.9-63.1%) in women with advanced maternal age and 39.8% (95% CI: 36.3-43.3%) in younger women.
Only the first embryo transfer in each ovarian stimulation cycle was included in this analysis. Overall, 683 embryos were transferred to 683 women who completed follow-up visits during pregnancy, with 436 embryos from younger women and 247 embryos from women with advanced maternal age. For the entire study, the biochemical pregnancy rate was 71.3% (487/683), the clinical pregnancy rate was 57.3% (391/683), the ongoing pregnancy rate was 54.5% (372/683) and the live-birth rate was 51.4% (351/683).
Embryonic aneuploidy rate stratified by gonadotropins dose
There was no association between gonadotropins dose and blastocyst aneuploidy rate within the same age group. Embryonic euploidy rates grouped by gonadotropins dose are shown in Fig. 1 .
In young women (<35 y.o., 537 PGS cycles), the embryonic aneuploidy rate was 42.9% (321/748) in the group of women with gonadotropins dose <1500 IU, 36.9% (372/1009) in the group of women with gonadotropins dose 1500-3000 IU and 43. 4% (86/198) in the group of women with gonadotropins dose >3000 IU. After adjusting for age, BMI and basal FSH, the total dose of exogenous gonadotropins was not associated with blastocyst aneuploidy (P > 0.05) (Table II) .
In patients with advanced maternal aged (≥35 y.o., 551 PGS cycles), no significant difference was identified in the aneuploidy rate by category of exogenous gonadotropins dose. The embryonic aneuploidy rate was 58.0% (181/312) in the group of women with low gonadotropin dose (<1500 IU), 59.8% (471/788) in the group of women with medium gonadotropin dose (1500-3000 IU) and 59.8% (98/164) in the group of women with high gonadotropin dose (>3000 IU) (P = 0.86).
Embryonic aneuploidy rate stratified by number of oocytes
A total of 11,955 oocytes (11.0 ± 6.3 per cycle) were retrieved. The average number of oocytes retrieved decreased with advanced maternal age (<35 y.o., 13.1 ± 6.1 oocytes; ≥35 y.o., 8.9 ± 5.8 oocytes).
In young women, there was no significant difference in the rate of aneuploid embryos by oocyte number category (1-5 (Fig. 2) .
Pregnancy outcomes stratified by gonadotropins dose
The analysis of this dataset demonstrated no significant difference between gonadotropins dose and biochemical pregnancy, clinical pregnancy, ongoing pregnancy and live-birth rates amongst women of both age categories (Fig. 3) .
There was no statistical significance in the live-birth rate by gonadotropins dosing category: 51.1% (115/225) low gonadotropins dose (<1500 IU), 51.3% (195/380) in the group of women with medium gonadotropins dose (1500-3000 IU) and 52.6% (41/78) in the group of women with high gonadotropins dose (>3000 IU) (P = 0.98).
Live-birth rate stratified by number of oocytes
There was no significant difference in biochemical pregnancy between ovarian response groups (quantified as the number of oocytes retrieved) (P = 0.45). However, the clinical pregnancy, ongoing pregnancy and live-birth rates were significantly lower in low ovarian responders (1-5 oocytes) when compared with normal (11-15 oocytes) and suboptimal (6-10 oocytes) ovarian responders (Fig. 4) . No significant difference in pregnancy outcomes (clinical pregnancy, ongoing pregnancy and live-birth rates) was identified when comparing either high versus normal responders, or suboptimal versus normal responders (Fig. 4) . Live-birth rates were significantly lower in low ovarian responders when compared with normal and suboptimal ovarian responders but not high ovarian responders ( [96/199] ; P = 0.01). The logistic regression analysis revealed that live-birth rate was associated with ovarian response, even after adjusting for female age, BMI, basal FSH and ovarian stimulation protocols (Table III) .
Discussion
This study demonstrates that the total dose of exogenous gonadotropins used for ovarian stimulation was not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women. Additionally, there were no significant differences between blastocyst rates. Based on the numbers before adjustment for confounding factors. BPR, biochemical pregnancy rate; CPR, clinical pregnancy rate; OPR, ongoing pregnancy rate; LBR, live-birth rate. *The CPR, OPR, LBR were significantly lower in low ovarian responders (1-5 oocytes) when compared with higher ovarian responders (P < 0.05).
aneuploidy and ovarian response (quantified as the number of oocytes retrieved). However, the clinical pregnancy, ongoing pregnancy and live-birth rates were significantly higher in higher ovarian responders when compared with lower ovarian responders (1-5 oocytes). PGS treatment is used for selecting embryos with euploid karyotypes to transfer, thereby enhancing the efficiency of the IVF outcomes (Brezina and Kutteh, 2015) . There is an increased incidence of embryonic aneuploidy in patients with unexplained recurrent miscarriage, recurrent implantation failure and advanced maternal age, which are the indications for PGS treatment (Donoso et al., 2007; Hodes-Wertz et al., 2012) . Labarta et al. (2017) reported that a higher ovarian response was related to a higher number of euploid embryos. To ensure at least one euploid blastocyst for transfer, the aim of ovarian stimulation for PGS is to obtain a relatively maximum ovarian response, especially for women with advanced maternal age.
Recently, mild ovarian stimulation with a low risk of complications and reduced economic burden has gained acceptance (Rinaldi et al., 2014) . Low doses of exogenous gonadotropins lead to a reduction in oocytes retrieved and to a decrease in the total live-birth rates (Drakopoulos et al., 2016) . Considering this, mild ovarian stimulation in PGS cycles can only be justified if this approach improves the pregnancy rates by minimizing embryonic aneuploidy. However, no significant difference was identified between the total dose of exogenous gonadotropins and the pregnancy outcomes in our study, including clinical pregnancy, ongoing pregnancy and live-birth rate. Additionally, women in the low-response category had reduced pregnancy rates (clinical pregnancy, ongoing pregnancy and live birth rates) in our analysis.
Reports on the effects of conventional versus mild ovarian stimulation in many instances present conflicting data (Verberg et al., 2009a) , but mild ovarian stimulation is thought to be safe in terms of reduction of ovarian hyperstimulation syndrome (OHSS) (Nargund et al., 2017) . Clinicians should consider the advantages of mild ovarian stimulation in IVF/ICSI treatment. However, the adverse consequences of high doses of gonadotropins on OHSS and endometrium receptivity may be reduced by frozen-embryo transfer in PGS cycles. Thus, without further proof of the advantages of mild ovarian stimulation when compared with conventional ovarian stimulation, milder ovarian stimulation may not be a strategy recommended in most patients undergoing PGS cycles.
The analysis of our data indicated that the ovarian response in terms of oocyte number retrieved is not detrimental to the percentage of embryonic euploidy. Despite the fear of obtaining no euploid embryos with a mild stimulation protocol, a negative relationship between excessive ovarian response (>20 oocytes) and adverse obstetric outcomes has been demonstrated (Sunkara et al., 2015) . Properly regulated ovarian stimulation options should be adapted to decrease oocyte and embryo wastage and adverse complications (Sunkara et al., 2011; Ghazal and Patrizio, 2017) . Barash et al. (Barash et al., 2017) reported that the ongoing clinical pregnancy and embryonic aneuploidy rates were not influenced by the gonadotropins dose used in ovarian stimulation. The dose of gonadotropins used in their study was 3332 ± 1241 IU in younger women and 5027 ± 1201 IU in women with advanced maternal age, which is far higher than that used for Han Chinese women (1897.2 ± 824.2 IU in younger women and 2084.3 ± 899.4 IU in women with advanced maternal age). Our study results reinforce the idea of their findings, showing that the blastocyst aneuploidy and pregnancy rates are independent of the gonadotropins dose in the Han Chinese population.
The study's limitations include its retrospective nature and the heterogeneity of the included patients. Another limitation of this study is that we did not evaluate the accuracy of our PGS platform. The accuracy of PGS has recently been under debate. Additionally, array-CGH may not be able to correctly identify mosaicism.
Undoubtedly, exogenous gonadotropins play an important role in assisted reproductive technology. The finding that gonadotropin dosage is not associated with embryonic aneuploidy or live-birth rates in Chinese women suggests that the high doses of gonadotropins used in ART cycles may be safe. 
